Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Imaging Biomarkers as Predictors of Visual Acuity in ABCA4 and PRPH2-Related Disease
Author Affiliations & Notes
  • Calvin Wayne Wong
    The University of Texas Health Science Center at Houston, Houston, Texas, United States
  • Troy Becker
    Retina Consultants of Texas, Houston, Texas, United States
  • Braden Nichols
    Retina Consultants of Texas, Houston, Texas, United States
  • Charles Clifton Wykoff
    Retina Consultants of Texas, Houston, Texas, United States
  • Kenneth Fan
    Retina Consultants of Texas, Houston, Texas, United States
  • Footnotes
    Commercial Relationships   Calvin Wong None; Troy Becker None; Braden Nichols None; Charles Wykoff 4DMT, AbbVie, Adverum, Aerie, AGTC, Alcon, Alimera, Allergan, Allgenesis, Alnylam, Annexon, Apellis, Arrowhead, Ascidian, Bausch + Lomb, Bayer, Bionic Vision Technologies, Boehringer Ingelheim, Cholgene, Clearside, Curacle, Eyebiotech, EyePoint, Foresite, Frontera, Genentech, Gyroscope, IACTA, IVERIC Bio, Janssen, Kato, Kiora, Kodiak, Kriya, Merck, Nanoscope, Neurotech, NGM, Notal Vision, Novartis, OccuRx, Ocular Therapeutix, Ocuphire, Ocuterra, OliX, ONL, Opthea, Oxular, Palatin, PerceiveBio, Perfuse, PolyPhotonix, Ray, RecensMedical, Regeneron, RegenXBio, Resonance, Roche, Sandoz, Sanofi, SciNeuro, Stealth, Surrozen, Suzhou Raymon, Takeda, THEA, Therini, TissueGen, Valo, Verana, Visgenx, Code C (Consultant/Contractor), 4DMT, Adverum, AffaMed, Alexion, Alimera, Alkahest, Allergan, Aldeyra, Allgenesis, Amgen, Annexin, Annexon, Apellis, Asclepix, Bayer, Boehringer Ingelheim, Chengdu Kanghong, Clearside, Curacle, Eyebiotech, EyePoint, Gemini, Genentech, GlaxoSmithKline, Graybug, Gyroscope, IONIS, iRENIX, IVERIC bio, Janssen, Kodiak, LMRI, McMaster University, Nanoscope, Neurotech, NGM, Novartis, Ocular Therapeutix, Ocuphire, OcuTerra, OliX, Ophthotech, Opthea, Oxurion, Oxular, Oyster Point, PerceiveBio, RecensMedical, Regeneron, RegenXBio, Rezolute, Roche, SamChunDang Pharm, Sandoz, Senju, Shanghai Henlius, Taiwan Liposome Co., UNITY, Verily, Xbrane, Code F (Financial Support), ONL, PolyPhotonix, RecensMedical, TissueGen, Visgenx, Vitranu, Code I (Personal Financial Interest); Kenneth Fan EyePoint Pharmaceuticals, Code C (Consultant/Contractor)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 5265. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Calvin Wayne Wong, Troy Becker, Braden Nichols, Charles Clifton Wykoff, Kenneth Fan; Imaging Biomarkers as Predictors of Visual Acuity in ABCA4 and PRPH2-Related Disease. Invest. Ophthalmol. Vis. Sci. 2024;65(7):5265.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Patients with ABCA4 and PRPH2-related diseases present with highly variable visual acuities and associated quality of life. Multiple subtypes of ABCA4 and PRPH2-related diseases with distinct phenotypes have been proposed, with visual prognosis being less thoroughly investigated. The present study aimed to identify imaging features to predict visual acuity among patients with these inherited retinal diseases.

Methods : Consecutive retrospective study of patients managed at an urban retina-based practice between 2016 and 2023. Patients with bi-allelic ABCA4 or PRPH2 molecular variants were included. Fundus autofluorescence and color photos were analyzed by 2 masked graders (KCF, CCW). Features noted on imaging included bone spicules, peripapillary sparing, flecks, bull’s-eye maculopathy, and chorioretinal atrophy (CRA). These imaging features were included in stepwise multiple regression models to predict logMAR best recorded visual acuity (BRVA) from chart review. This study was done under IRB approval according to the Declaration of Helsinki.

Results : 92 eyes from 46 patients were studied in the ABCA4 group model. Predictors of worse BRVA included peripapillary sparing, hypoautofluorescent macular CRA, and macular bone spicules in ABCA4 disease, while presence of macular flecks was associated with preserved vision (all p <0.01, R2=0.58). 44 eyes from 22 patients were studied in the PRPH2 group model. Macular bone spicules were associated with worse BRVA (p < 0.01), while bull’s-eye maculopathy and peripapillary sparing were associated with preserved vision (p <0.05, R2=0.46).

Conclusions : This study identified risk and protective factors for visual outcome in patients with ABCA4 retinopathies and PRPH2-related disease. In both groups, the presence of bone spicules in the macula were strongly associated with worse vision. Macular flecks were associated with better vision in the ABCA4 group while bull’s-eye maculopathy was associated with preserved vision in the PRPH2 group. Due to the exceeding variability in visual acuity and phenotype in these diseases, further multivariable analysis with larger, more diverse populations is warranted to further understand these potential prognostic indicators.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×